




"Lupoid" nephritis. D. Adu, D. G. Williams, D. Taube, A.R. Vilches,
D.R. Turner, J.S. Cameron, and C.S. Ogg. Renal Unit, Guy's Hospi-
tal, London, England. Some patients with a glomerulonephritis do not
fall easily into the accepted definitions of idiopathic glomerulonephritis
and systemic lupus erythematosus (SLE), thus raising problems of
classification, prognosis, and most importantly treatment. We report
data on 18 such patients who presented with either an apparent
idiopathic glomerulonephritis (17 patients) or poststreptococcal glomer-
ulonephritis. Doubts arose about these patients because they presented
possible clinical features of SLE without serologic confirmation, sug-
gestive serologic abnormalities in the absence of clinical features of
SLE, or a renal biopsy suggestive of SLE in the absence of either. The
ages at onset of nephritis ranged from 14 to 63 years (mean, 39.8 yr); 11
were male and 7 female. Three patients had a positive antinuclear
antibody test at the onset of their illness, and in another 4 serum binding
of double-stranded DNA (dsDNAB) was only just elevated (30, 31, 33,
38 u/mI, normal < 25). Ten patients had a predominant membranous
glomerulonephritis (GN), 4 subendothelial mesangiocapillary GN
(MCGN), 2 focal segmental glomerulosclerosis (FSCS), and one each
focal proliferative glomerulonephritis and diffuse endocapillary GN. On
1 m renal sections, 10 patients had immune deposits at multiple sites in
the glomeruli (membranous GN 6, MCGN 3, focal proliferative GN 1).
Over a followup period of Ito 14 years, 14 of the 18 patients developed
raised serum levels of dsDNAB (38 to 105 u/mI) and 8 patients with
raised serum levels of dsDNAB clinical features suggestive of SLE
(arthralgia 4, rash 3, pericarditis I, pleurisy I, fibrosing alveolitis I,
arteritis 1, episcleritis 1, and polychondritis 1). Only one patient was
hypocomplementemic at onset of the illness (C3, 49%) but subsequently
7 patients became hypocomplementemic (low C4 in 3 and low C3 in 4).
Sera from 14 patients were examined for cryoglobulins, and these were
found in 12 patients. Nine of the 12 cryoglobulins contained DNA
(ethidium bomide technique) at a concentration 0.29 to 46.2 g/mg
cryoprotein. Cryoglobulin IgG was isolated by acid dissociation and
ultracentrifugation of 9 cryoglobulins. Six of the 9 IgG fractions had
anitbody activity directed against dsDNA as well as ssDNA. Of 12
patients treated with steroids and immunosuppressants (combined with
anticoagulants in 4), 7 responded with a rise in GFR (range, II to 100;
mean, 30 mI/mm) and 7 lost their nephrotic syndrome. On the basis of
the clinical, histologic, and serologic observations and followup, these
patients can be classified now as follows. Group 1. Definite SLE: 8
patients with a predominant membranous UN (5) or MCGN (3), all of
whom developed a positive ANA and raised serum levels of dsDNAB.
Six patients developed extrarenal features suggestive of SLE, and 7 had
on histology, immune deposits at multiple sites in the glomeruli. Group
2. Probable SLE: 3 patients with a membranous GN (subepithelial
deposits only), raised serum levels of dsDNAB but no extrarenal
manifestations. Group 3. Possible SLE: 2 patients with FSGS, raised
serum levels of dsDNAB and extrarenal manifestations (rash and
polychondritis in one, rash, arthralgia and episcleritis in the other).
Group 4. "Multiple deposit" group: 4 patients (2 with a predominant
membranous GN, one MCGN and one focal proliferative GN) none of
whom have developed extrarenal features of SLE or raised serum levels
of dsDNAB. This group probably represents an unusual variety of
idiopathic glomerulonephritis. Group 5. Poststreptococcal glomerulo-
nephritis, but with raised serum levels of dsDNAB. SLE may present
with a nephritis as the sole disease manifestation, antedating other
clinical features and even the immunologic markers of this disease;
furthermore, some patients with a glomerulonephritis may show clinical
and/or immunologic or histologic features of SLE but do not fit
accepted definitions of SLE.
Serum silicon in hemodialyzed patient. J. W. Dobbie, M.J.B. Smith, L.
Erwin, and F.J. Goodwin. University Department of Medicine, Glas-
gow Royal Infirmary, Glasgow, Scotland and Department of Nephrolo-
gy, The London Hospital, London, England. We have previously
shown that the kidney is the main excretory organ for dietary absorbed
silicon (Si), and that hypersilicaemia is a feature of uremia. In this study
we have measured serum Si in 58 patients on hemodialysis in 4 different
centers, before and after a 4- to 6-hour dialysis, and correlated these
levels with the Si content of the local tap water and the dialysate. In
Glasgow Royal Infirmary, the concentration of Si in tap water was 14
and in the dialysate 20 imoles/liter. The mean predialysis serum Si was
45 moles/liter (N = 18; SD 7; range, 28 to 57) and postdialysis Si 30
moles/liter (SD 5; range, 25 to 43), giving a mean fall of 33%. In
Edinburgh Western General Infirmary, the concentration of Si in tap
water was 78 and in the dialysate 80 moles/liter. The mean predialysis
serum Si was 81 moles/liter (N = 5; SD 16; range, 68 to 107) and
postdialysis Si was 85 mo1es/liter (SD 16; range, 78 to 100) giving a
mean rise of 8%. In Edinburgh Royal Infirmary, the concentration of Si
in tap water was 78 and in the dialysate 80 imoles/liter. After reverse
osmosis, dialysate Si fell to 34 imoles/liter. The mean predialysis serum
Si was 59 lJ.moles/liter (N = 19; SD 12; range, 39 to 82) and
postdialysis Si 37 p.moles/liter (SD 8; range, 78 to 100) giving a mean
fall of 35%. In the London Hospital, the concentration of Si in tap water
was 142 and in the dialysate 186 p.moles/liter. The mean predialysis
serum Si was 149 iimoles/liter (N = 16; SD 17; range, 121 to 174) and
postdialysis Si 173 moles/liter (SD 19; range, 139 to 217) giving a
mean rise of 16%. This investigation has thus demonstrated a significant
regional variation in serum Si in hemodialysis patients, which is related
to the Si content of the dialysate.
Increased platelet sensitivity and spontaneous platelet aggregation in
the nephrotic syndrome. C.A. Jackson, F.E. Preston, C.B. Brown, and
A. Patterson. University Department of Haematology and Department
of Nephrology, Royal Hallamshire Hospital, Sheffield, England. Pa-
tients with nephrotic syndrome have an increased tendency to thrombo-
sis. In an attempt to assess the contribution of platelets to this
thrombotic tendency, we investigated the relationship between platelet
aggregation, thromboxane A2 (TXA2) production, and plasma albumin
concentration. Fifteen patients with nephrotic syndrome were studied.
TXA2 generation induced by collagen and sodium arachidonate (NaAA)
was assessed by radioimmunoassay of the stable metabolite TXB2.
Platelet aggregation responses to ADP, collagen, and NaAA were
measured, and the sensitivity threshold to each agent was determined.
The group of nephrotic patients showed significantly enhanced aggrega-
tion responses to all aggregating agents, particularly NaAA. The
patients also produced significantly more TXA2 in response to NaAA
than controls but production in response to collagen was similar to
control values. Spontaneous platelet aggregation was observed in 5 of
the 15 patients, and this could be abolished by in vitro addition of
albumin. Sensitivity of NaAA aggregation correlated well with plasma
albumin levels. No similar correlation was found using ADP or colla-
gen, although the addition of albumin reduced platelet sensitivity to
these agents. TXA2 production in response to NaAA was reduced by
albumin, but no similar effect was observed with collagen-induced
production. The increased platelet sensitivity seen in the nephrotic
syndrome has in the past been attributed to hypoalbuminemia, with
resultant increased availability of arachidonic acid for conversion to
proaggregatory products. Other possible mechanisms should not be
overlooked, however, as albumin appears to exert an inhibitory effect
on platelet aggregation which is unrelated to the synthesis of TXA2.
Adrenergic control of the circulation in hemodialyzed patients. RB.
Naik, C.J. Mathias, J.L. Reid, and D.J. Warren. Department of Renal
Medicine, University of Southampton, and St. Mary's Hospital, Ports-
mouth, England, and Department of Materia Medica, University of
Glasgow, Scotland. We have extended our studies on the possible role
of autonomic dysfunction in circulatory control in hemodialyzed pa-
tients by measuring plasma noradrenaline (PNA) levels by radioenzy-
matic assay before and immediately after hemodialysis in 14 patients
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with chronic renal failure. Comparisons were made with 10 normal
subjects. Blood pressure (BP) and heart rate (HR) responses to i.v.
infusions of noradrenaline (0.02 to 0.15 g/kg/min) and isoprenaline
(0.02 g/kg/min) and HR responses to i.v. boluses of isoprenaline (0.004
to 0.04 pi.g/kg) and atropine (0.005 to 0.03 mg/kg) were measured in both
groups. Plasma renin activity (PRA) was measured by radio-
immunoassay before, during, and after infusion of isoprenaline (0.02 g/
kg/mm) in both patients and normal subjects. Our results indicate higher
resting PNA levels in patients compared with normal subjects. The
PNA response to head-up tilt was similar to the response in normal
subjects and was not influenced by hemodialysis. The dose-response
curves of BP and HR to noradrenaline and isoprenaline were similar in
both groups. The HR responses to bolus isoprenaline and atropine
appeared less in patients than in normal subjects. The resting HR,
however, was significantly higher in patients than in normal subjects (76
6 and 63 3 beats/mm, respectively). Infusion of 0.02 j.g/kg/min of
isoprenaline raised PRA in normal subjects but not in patients. Our
results suggest that alpha-adrenoceptor-mediated responses are similar
in hemodialyzed patients and normal subjects. Beta-adrenoceptor-
stimulated renin release appears defective in the patients. The impaired
HR responses to bolus isoprenaline and atropine may be partly ex-
plained by a higher resting HR in the patients. This may be the result of
increased sympathetic efferent activity, reduced vagal tone, presence of
an arteriovenous fistula, or a combination of these reasons. The
impaired HR responses may therefore not imply organic cardiac beta-
adrenoceptor or vagal involvement.
Renal function after cardiopulmonary bypass surgery. S.P.A. Rigden,
T.M. Barratt, M.J. Dillon, M. de Leval, and J. Stark. Department of
Nephrology, Institute of Child Health, London and Thoracic Unit,
Hospital for Sick Children, Great Ormond Street, London, England. A
prospective study of acute renal failure (ARF) following cardiopul-
monary bypass surgery (CPBS) was undertaken in the 456 children
operated on in 1978 to 1979. Twenty four (5.3%) developed ARF, and of
those 15 (63%) recovered renal function. The incidence of ARF was
significantly greater in children with complex lesions, those under one
year of age and those with overall bypass plus arrest times over 90 mm.
In an unselected series of children undergoing CPBS, plasma creatinine
rose an average of 41% on the first postoperative day, and the urinary
excretion of N-acetyl glucosaminidase (UNAG) rose sixfold; there was
a significant correlation between these two phenomena. A prospective
comparison of gentamicin and cephalothin was undertaken in high-risk
children: UNAG excretion was significantly greater in the gentamicin
treated group, but plasma creatinine concentrations did not differ
significantly. However, a prospective comparison of mannitol prophy-
laxis showed lower plasma creatinine concentrations in the treated
group from the 3rd to 5th postoperative day, but no differences in
UNAG. Studies of postoperative renal function are a sensitive index of
the adequacy of surgical and bypass techniques.
Long-term experience of alfacalcidol in renal osteodystrophy. V.L.
Sharman, A.M. Brownjohn, W. Hately, J.L.H. O'Riordan, SE. Papa-
poulos, F.J. Goodwin, and F.P. Marsh. Departments of Nephrology
and Radiology, The London Hospital, and Department of Medicine,
The Middlesex Hospital, London, England. Thirteen patients receiving
regular hemodialysis therapy, with biochemical or radiologic evidence
of renal osteodystrophy, were given alfacalcidol (1-aipha-hydroxycho-
lecalciferol) for 4 years in doses varying from 3 g daily to I ig weekly.
Serum parathyroid hormone (SPTH), raised before treatment, fell from
4.47 0.53 (mean SEM) ng/ml to 1.33 0.34 at 1 '/2years, but rose to
2.77 0.88 at 4 years. In only 5 patients (group A, responders) was
SPTH normal at 4 years. In 5 patients (group B, transient responders)
SPTH, which had been normal at 11/2 years, was raised at 4 years. In 3
patients (group C, nonresponders) SPTH never became normal. Plasma
alkaline phosphatase (PAP), raised before treatment in 11 patients, fell
from 220 34 U/liter to 89 21 at 1 V2 years, becoming normal in all but
one patient within 15 months. It rose to 151 32 at 4 years, when it was
normal in only 4 patients (2 in group A and 2 in group B). The times
taken for SPTH and PAP to become normal were closely correlated (r =
0.84, P < 0.01). A close relationship was found between the changes in
SPTH and PAP (r = 0.85, P < 0.01) and a negative correlation between
the changes in SPTH and plasma calcium (r, = 0.74, P < 0.01,
Spearman rank correlation). Plasma calcium rose in all patients, ex-
ceeding 2.6 mmoles/liter in 12 and 3.0 mmoles/liter in 10. It usually rose
abruptly close to the time when PAP became normal and often
remained raised despite reduction in dosage of alfacalcidol. Radiologi-
cally, all patients had subperiosteal phalangeal erosions which im-
proved during the first year of therapy. After 4 years' treatment,
erosions had healed in 6 patients but were still present in 7, having
become more marked in 4. Rib fractures were present in 4 patients
before treatment, healing in 3, deteriorating in one, and developing in
one other patient during the study. Vascular calcification increased in 2
patients, and soft tissue calcification progressed in one other patient
during alfacalcidol therapy. Alfacalcidol appeared effective during the
first year of treatment but subsequently biochemical and radiologic
response was variable, and treatment was often complicated by hyper-
calcaemia. We have reservations about the ultimate value of long-term
therapy with alfacalcidol in hemodialyzed patients with renal osteodys-
trophy and urge caution in its use.
Diagnosis of allograft rejection by computer. I. Trimble, M. West,
MS. Knapp, and A. Smith. City Hospital and University of Notting-
ham, Nottingham, England. New statistical methods based on Bayes'
Theorem define trends in sequences of results, reflecting either im-
provement, deterioration or stability, and can express the probability
that a new trend is developing. When a result becomes available it is
possible, using this approach, to determine whether the previous result
showed (1) a continuation of the previous trend; (2) a transient change
(e.g., laboratory error); (3) a change in level (e.g., after dialysis) or (4) a
change in slope (e.g., a change in renal function as a consequence of
rejection), and so determine the probability that the new result repre-
sents a significant change. A computer program has been developed
that detects changes in slope, and filters Out changes of little clinical
concern such as improving function, laboratory error, and level changes
due to dialysis. The sensitivity of the system is governed by the total
variance in the data. The program automatically responds to changes in
variance due to the laboratory assay, to variation in the timing of
sample collection, and to truncation of numerical results. Sequence of
plasma creatinine results from 28 patients over a period of 60 days after
transplantation were analyzed. The computer identified prospectively
26 out of 28 episodes considered, by subsequent clinical review, to be
allograft rejection. The computer diagnosis was earlier, by a median of
one day (P < 0.01), than a clinican's review, and one day earlier (P <
0.01) than the time when treatment was given. In the same patients, the
results of urine analyses for sodium, potassium, and creatinine concen-
trations were analyzed using the Kalman filter, Thirty-five out of 47
(74%) episodes of renal impairment identified by the computer from
plasma creatinine results were identified by analysis of the urine data.
Computer analysis of urinary measurement may, with further program
modification, provide an even earlier alerting system than plasma
values, and one that is potentially suitable for self-monitoring by the
patient.
Hemodialysis-induced endothelial damage: A mechanism for athero-
genesis in uremia. J.H. Turney and M.J. Weston. King's College
Hospital Renal Unit, Dulwich Hospital, London, England. The uremic
hemorrhagic diathesis is characterized by a prolonged capillary bleed-
ing-time and decreased platelet adhesion within glass-bead columns.
Paradoxically, cardiovascular disease is the commonest cause of death
in dialyzed patients, and there is evidence that they develop atheroscle-
rosis of a severity disproportionate to the degree of hypertension. The
proven involvement of platelets in atherogenesis would seem to be at
variance with the demonstrable platelet abnormality in uremia. In a
study of 41 patients receiving regular dialysis therapy, we found
elevated levels of factor VIII antigen (264.8% LSD] 158.8 of pooled
normal plasma), factor VIII coagulant activity (218.2 107.3%), and
fibrinogen (379.3 114.9 mg/dI), and decreased antithrombin III (91.2
19.0%) (all results P < 0.0005, compared with normal controls).
These results are evidence of a "prothrombotic state," which may lead
to intravascular coagulation, as shown by the widened ratio between
factor VIII antigen and coagulant activity. Hemodialysis with heparin
alone leads to a fall in platelet count and a rise in 3-thromboglobulin,
which persists throughout dialysis, indicating continuing platelet activa-
tion. Similarly, there is a progressive rise in antithrombin III (to 152.9
1.6% of predialysis values) and factor VIII antigen (to 131.3 7.7%;
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both results P < 0.0001), both of which are derived from activated
platelets and also vascular endothelium damaged by the reinfusion
during dialysis of activated platelets, leukocytes, complement, etc.
These changes can be prevented by the administration of prostacyclin.
There is therefore evidence of a prothrombotic state, low-grade intra-
vascular coagulation, and endothelial damage induced by hemodialysis.
The coexistence of these coagulation abnormalities with other risk
factors in uremia provide a mechanism for atherogenesis in dialysis
patients. However, ristocetin-induced platelet aggregation is reduced in
chronic uremia (optical density/mm 50.5 21.7, cf controls 79.9
17.0, P < 0.0001) and is further depressed in dialyzed patients (37.5
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17.2, P < 0.001, cf undialyzed chronic uraemics). This defect may be
transferred to normal platelets by dialyzed uremic plasma, indicating
the presence of a nondialyzable inhibitor of ristocetin-induced aggrega-
tion. This defect of the platelet membrane glycoprotein-von Willebrand
factor interaction explains the decreased adhesion to glass beads and
prolonged capillary bleedingtime. However, this abnormality does not
necessarily impair platelet aggregation to common stimulants such as
ADP, collagen, and thrombin. The demonstration of this acquired
defect of platelet function allows the anomalous coexistence of a
prolonged bleeding-time with the development of atherosclerosis in
uremia.
